EPHB4 mutations in dilated cardiomyopathy
暂无分享,去创建一个
J. Haas | F. Sedaghat-Hamedani | B. Meder | G. Luxán | M. Muhly-Reinholz | S. Glaser | J. Trebing | S. Dimmeler | C. Reich
[1] S. Dimmeler,et al. A coalition to heal—the impact of the cardiac microenvironment , 2022, Science.
[2] Catherine L. Worth,et al. Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies , 2022, Science.
[3] T. Walther,et al. A human cell atlas of the pressure-induced hypertrophic heart , 2022, Nature Cardiovascular Research.
[4] S. Dimmeler,et al. The vasculature: a therapeutic target in heart failure? , 2021, Cardiovascular research.
[5] K. Klingel,et al. Single Nuclei Sequencing Reveals Novel Insights Into the Regulation of Cellular Signatures in Children With Dilated Cardiomyopathy , 2021, Circulation.
[6] Daowen Wang,et al. The role of CD36 in cardiovascular disease , 2020, Cardiovascular research.
[7] K. Red-Horse,et al. Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction , 2020, bioRxiv.
[8] E. Boersma,et al. Circulating Biomarkers of Cell Adhesion Predict Clinical Outcome in Patients with Chronic Heart Failure , 2020, Journal of clinical medicine.
[9] G. Hindricks,et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). , 2020, European heart journal. Quality of care & clinical outcomes.
[10] Juan M. Vaquerizas,et al. Endothelial EphB4 maintains vascular integrity and transport function in adult heart , 2019, eLife.
[11] S. Blankenberg,et al. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes , 2019, Journal of internal medicine.
[12] M. Suematsu,et al. Myocardial fatty acid uptake through CD36 is indispensable for sufficient bioenergetic metabolism to prevent progression of pressure overload-induced heart failure , 2018, Scientific Reports.
[13] S. Bagdasarov,et al. Endothelial cell CD36 optimizes tissue fatty acid uptake , 2018, The Journal of clinical investigation.
[14] B. Maron,et al. Classification, Epidemiology, and Global Burden of Cardiomyopathies. , 2017, Circulation research.
[15] Hugo A. Katus,et al. Data privacy management and data quality monitoring in the German Centre for Cardiovascular Research's multicentre TranslatiOnal Registry for CardiomyopatHies (DZHK‐TORCH) , 2017, ESC heart failure.
[16] W. Hoffmann,et al. TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results , 2017, ESC heart failure.
[17] J. Dyck,et al. Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure. , 2017, American journal of physiology. Heart and circulatory physiology.
[18] D. Hedges,et al. Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.
[19] B. Funke,et al. Dilated cardiomyopathy , 2007, Archives of Disease in Childhood.
[20] R. Adams,et al. Eph/ephrin molecules--a hub for signaling and endocytosis. , 2010, Genes & development.
[21] C. Folmes,et al. Myocardial fatty acid metabolism in health and disease. , 2010, Physiological reviews.
[22] P. Verkade,et al. Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. , 2006, Biochimica et biophysica acta.
[23] D. Y. Lee,et al. Substitution of aspartic acid with glutamic acid increases the unfolding transition temperature of a protein. , 2004, Biochemical and biophysical research communications.
[24] P. Brzovic,et al. Substitution of glutamic acid 109 by aspartic acid alters the substrate specificity and catalytic activity of the beta-subunit in the tryptophan synthase bienzyme complex from Salmonella typhimurium. , 1992, Biochemistry.
[25] J. Chang,et al. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. , 1986, The Journal of biological chemistry.